Triglycidyl isocyanurate(Synonyms: TGIC; Teroxirone)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Triglycidyl isocyanurate (Synonyms: TGIC; Teroxirone) 纯度: ≥98.0%

Triglycidyl isocyanurate (TGIC; Teroxirone) 是一种具有抗血管生成和抗肿瘤活性的三氮烯三环氧化合物。Triglycidyl isocyanurate 通过 p53 的激活抑制非小细胞肺癌细胞的生长。Triglycidyl isocyanurate 诱导细胞凋亡 (apoptosis)。Triglycidyl isocyanurate 可用于癌症研究。

Triglycidyl isocyanurate(Synonyms: TGIC; Teroxirone)

Triglycidyl isocyanurate Chemical Structure

CAS No. : 2451-62-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550 In-stock
500 mg ￥500 In-stock
1 g ￥750 In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

Triglycidyl isocyanurate 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Covalent Screening Library
  • Ferroptosis Compound Library
  • Pyroptosis Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research[1][2].

体外研究
(In Vitro)

Triglycidyl isocyanurate (0-30 μM; 48 hours) reduces the growth of spheroids of human non-small-cell-lung cancer cells in culture, it leads to a gradual reduction in size for tumorspheres of A549, H460 and H1299 cells[1].
Triglycidyl isocyanurate (0-30 μM; 48 hours) inhibits expression of akt1/2/3 and phosphorylated Aktser473/474/472 of A549, H460 and H1299 tumorspheres, however, the cleavage of PARP and procaspase-3 plus the emergent active caspase-3 fragment are only visible in H460 and A549 tumorspheres[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: A549, H460 and H1299 cells
Concentration: 0 μM; 5 μM; 10 μM; 30 μM
Incubation Time: 48 hours
Result: Inhibited tumor cells growth in soft agar.

Western Blot Analysis[1]

Cell Line: A549, H460 and H1299 cells
Concentration: 0 μM; 5 μM; 10 μM; 30 μM
Incubation Time: 48 hours
Result: Inhibited akt1/2/3 expression and p-aktser473/474/472 expression of A549, H460 and H1299 tumorspheres

体内研究
(In Vivo)

Triglycidyl isocyanurate (subcutaneous injection; 1.8 and 3.6 mg/kg; every 2–3 days for total seven times; 30 days) suppresses the growth of xenograft tumors and has no effects on weight in nude mice[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nu/nu mice with Huh7 cells subcutaneously injected into the dorsal area[2]
Dosage: 1.8 mg/kg and 3.6 mg/kg
Administration: Subcutaneous injection; every 2–3 days for total seven times; 30 days
Result: Inhibited the growth of xenograft tumors.

分子量

297.26

Formula

C12H15N3O6
CAS 号

2451-62-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (168.20 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.3641 mL 16.8203 mL 33.6406 mL
5 mM 0.6728 mL 3.3641 mL 6.7281 mL
10 mM 0.3364 mL 1.6820 mL 3.3641 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Yu-Ling Ni, et al. Teroxirone motivates apoptotic death in tumorspheres of human lung cancer cells. Chem Biol Interact. 2018 Aug 1;291:137-143

    [2]. Seung-Hun Kim, et al. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells.Biomed Pharmacother. 2018 Mar;99:997-1008

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务